TY - JOUR
T1 - Protective effect and duration of action of formoterol aerosol on exercise-induced asthma
AU - Patessio, A.
AU - Podda, A.
AU - Carone, M.
AU - Trombetta, N.
AU - Donner, C. F.
PY - 1991
Y1 - 1991
N2 - The short-term protective effect on exercise-induced asthma (EIA) and the duration of action of formoterol, given by metered dose aerosol at a dose of 24 μg, were compared with salbutamol (200 μg) and placebo in twelve asthmatic EIA-positive patients in a double-blind, placebo-controlled, three period cross-over study. On each treatment day the patients were given one of the drugs or placebo and two exercise tests were performed at the second and at the eighth hour after dosing. Using a standard procedure, exercise was performed by treadmill in well-controlled environmental conditions. In the first test at 2 h a significant difference relative to placebo (p <0.001) at each incremental time after exercise (i.e. 5, 10, 15, 20, 30 min) was obtained with both formoterol and salbutamol, without any significant difference between formoterol and salbutamol. After the eighth hour test formoterol still protected against EIA in comparison to both salbutamol and placebo. The effect of salbutamol at this time was not different from placebo. No adverse effects were reported in any treatment group. Formoterol has a long duration of action in protecting against EIA that persisted for eight hours, removing the need to dose with β2-agonist before every exercise.
AB - The short-term protective effect on exercise-induced asthma (EIA) and the duration of action of formoterol, given by metered dose aerosol at a dose of 24 μg, were compared with salbutamol (200 μg) and placebo in twelve asthmatic EIA-positive patients in a double-blind, placebo-controlled, three period cross-over study. On each treatment day the patients were given one of the drugs or placebo and two exercise tests were performed at the second and at the eighth hour after dosing. Using a standard procedure, exercise was performed by treadmill in well-controlled environmental conditions. In the first test at 2 h a significant difference relative to placebo (p <0.001) at each incremental time after exercise (i.e. 5, 10, 15, 20, 30 min) was obtained with both formoterol and salbutamol, without any significant difference between formoterol and salbutamol. After the eighth hour test formoterol still protected against EIA in comparison to both salbutamol and placebo. The effect of salbutamol at this time was not different from placebo. No adverse effects were reported in any treatment group. Formoterol has a long duration of action in protecting against EIA that persisted for eight hours, removing the need to dose with β2-agonist before every exercise.
KW - Duration of action
KW - Exercise-induced asthma
KW - Formoterol
KW - Salbutamol
UR - http://www.scopus.com/inward/record.url?scp=0025877637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025877637&partnerID=8YFLogxK
M3 - Article
C2 - 1677894
AN - SCOPUS:0025877637
VL - 4
SP - 296
EP - 300
JO - European Journal of Respiratory Diseases
JF - European Journal of Respiratory Diseases
SN - 0903-1936
IS - 3
ER -